Four leading cancer research organizations will host a conference dedicated to the latest in cancer immunotherapy.
15-Aug-2016 12:05 PM EDT Add to Favorites
Media are encouraged to register to attend the second annual International Cancer Immunotherapy Conference organized by the Cancer Research Institute, Association for Cancer Immunotherapy, European Academy of Tumor Immunology, and the American...
3-Aug-2016 12:00 PM EDT Add to Favorites
Cancer Research Institute to Honor Three Scientists for Outstanding Contributions to Cancer Immunotherapy Research
Announcement of winners of the 2016 William B. Coley and Frederick W. Alt Awards, celebrating key scientific contributions to the fields of immunology, tumor immunology (also known as immuno-oncology), and cancer immunotherapy.
26-Jul-2016 1:00 PM EDT Add to Favorites
Month-long educational and awareness initiative designed increase public awareness of the potential of cancer immunotherapy to treat and potentially cure all cancers.
1-Jun-2016 2:05 PM EDT Add to Favorites
One-day, multi-distance ride through the Lower Hudson Valley’s breathtaking landscape to raise funds for the nonprofit Cancer Research Institute and increase awareness of the potential of immunotherapy to cure all cancers.
12-May-2016 12:00 PM EDT Add to Favorites
CRI and Inspire have partnered to launch a new cancer immunotherapy support community for patients and caregivers.
11-Apr-2016 10:00 AM EDT Add to Favorites
Immunotherapy is currently revolutionizing cancer treatment and, according to Axel Hoos, M.D., Ph.D., has the potential to improve patient outcomes significantly in the future. Dr. Hoos leads one of the Cancer Research Institute’s (CRI)...
23-Mar-2016 11:05 AM EDT Add to Favorites
New hope now exists for patients with advanced kidney cancer. Yesterday, the FDA approved the immunotherapy drug nivolumab (Opdivo®, Bristol-Myers Squibb) to treat metastatic renal cell carcinoma (RCC)—the most common form of kidney cancer—that...
2-Dec-2015 2:05 PM EST Add to Favorites
The FDA announced on Aug 4 2009 that tumor necrosis factor (TNF) blockers used in the treatment of immune disorders carry an increased risk of lymphoma and other cancers in children and adolescents. The discoverer of TNF-alpha, Lloyd J. Old, M.D., a...
7-Aug-2009 9:00 AM EDT
Dendreon's PROVENGE for the treatment of advanced prostate cancer is the first active cellular immunotherapy to prolong patient survival, according to data from a pivotal phase III clinical trial announced at yesterday's AUA annual meeting in...
29-Apr-2009 11:20 AM EDT